Spontaneous bacterial peritonitis a review of treatment options

P and T

Volumn 34, Issue 4, 2009, Pages 204-213

  Alaniz, Cesar ^a   Regal, Randolph E ^a,b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BILIRUBIN; CEFONICID; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; CREATININE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; NORFLOXACIN; OFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL TENDERNESS; ACUTE KIDNEY FAILURE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ASCITES; ASCITES FLUID ANALYSIS; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIOLOGY; BACTERIUM ISOLATE; BILIRUBIN BLOOD LEVEL; BLOOD CULTURE; CHILL; CITROBACTER FREUNDII; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; ENTEROBACTER; ENTEROBACTER CLOACAE; ENTEROCOCCUS; ESCHERICHIA COLI; FECES CULTURE; FEVER; GASTROINTESTINAL HEMORRHAGE; GRAM POSITIVE BACTERIUM; GRAM STAINING; HEALTH CARE COST; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; KIDNEY DISEASE; KLEBSIELLA OXYTOCA; LIVER CIRRHOSIS; MENTAL DETERIORATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MORTALITY; NAUSEA; NEUTROPHIL COUNT; PARACENTESIS; PATHOGENESIS; PATHOGENICITY; PERITONITIS; PROVIDENCIA RETTGERI; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEPSIS; SPONTANEOUS BACTERIAL PERITONITIS; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINE CULTURE; VOMITING;

EID: 66949112943     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Such J, Runyon A. Spontaneous bacterial peritonitis. Clin Infect Dis 1998;27:669-676.
2. Gines P, Arroyo V, Rodes J. Therapy of ascites and spontaneous bacterial peritonitis. In: Cohen S, Davis GL, Gianella RA, et al., eds. Therapy of Digestive Disorders: A Companion to Sleisenger and Fortran's Gastrointestinal and Liver Disease. Philadelphia: WB Saunders, 2000:373-384.
3. Runyon A. Spontaneous bacterial peritonitis: An explosion of information. Hepatology 1988;8:171-175.
4. Navasa M, Folio A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996:111:1011-1014.
5. Runyon BA, McHutchinson JG, Antillon MR, et al. Short course vs. long course antibiotic treatment of spontaneous bacterial peritonitis: A randomized controlled trial of 100 patients. Gastroenterology 1991;100:1737-1742.
6. Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. Hepatology 1988;8:27-31.
7. Andreu M, Sola, R, Sitges-Serra A, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993;104:1133-1138.
8. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: Variations on a common theme. Medicine 1971;50:161-197.
9. Pinzello G, Simonetti RG, Craxi A, et al. Spontaneous bacterial peritonitis: A prospective investigation in predominantly nonalcoholic cirrhotic patients. Hepatology 1983;3:545-549.
10. Weinstein MR Iannini PB, Stratton CW, et al. Spontaneous bacterial peritonitis: A review of 28 cases with emphasis on improved survival and factors influencing prognosis. Am J Med 1978;64: 592-598.
11. Hoefs JC, Runyon BA. Culture-negative neutrocytic ascites: A variant of spontaneous bacterial peritonitis. Hepatology 1984;4: 1209-1211.
12. Runyon BA Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988; 8:632-635.
13. Fox RA, Dudley FS, Sherlock S. The serum concentrations of the third component of complement in liver disease. Gut 1971;12: 574-578.
14. Kourilsky O, LeRoy C, Peltier AP. Complement and liver cell function in 53 patients with liver disease. Am J Med 1973;55: 783-790.
15. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing, and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-262.
16. Rimola A, Soto R, Bory F, et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53-58.
17. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986;91:1343-1346.
18. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Br J Surgery 1973;60: 646-649.
19. Bandy SM, Tuttle A Spontaneous bacterial peritonitis. E-medicine from WebMD. Updated July 16, 2008.
20. Runyon BA, Morrisey R, Hoefs JC, et al. Opsonic activity of human ascitic fluid: A potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985;5: 634-637.
21. Kurtz RC, Bronzo RL. Does spontaneous bacterial peritonitis occur in malignant ascites? Am J Gastroenterol 1982;77:146-148.
22. Runyon BA. Spontaneous bacterial peritonitis associated with cardiac ascites. Am J Gastroenterol 1984;79:796.
23. Llach J, Rimola A, Navasa M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-727.
24. Hoefs JC, Canawati HN, Sapico FC, et al. Spontaneous bacterial peritonitis. Hepatology 1982;2:399-407.
25. Carey WD, Boayke A, Leatherman J. Spontaneous bacterial peritonitis: Clinical and laboratory features with reference to hospital-acquired cases. Am J Gastroenterol 1986;81:1156-1161.
26. Johnson CC, Baldessarre J, Levison ME. Peritonitis: Update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997;24:1035-1047.
27. Runyon BA, Antillon MR, Akriviadis EA, et al. Bedside inoculation of blood culture bottles with ascitic fluid is superior to delayed inoculation in the detection of spontaneous bacterial peritonitis. Clin Microbiol 1990;28:2811-2812.
28. Wong CL, Holroyd-Leduc J, Thorpe KE, et al. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results? JAMA 2008;299: 1166-1178.
29. Roberts GH, Ramsey MK. Guidelines for interpretation of the routine urinalysis. Consultant Pharmacist 1990;5:748-756.
30. Castellote J, Lopez C, Gornals J, et al. Rapid diagnosis of spontaneous bacterial peritonitis by use of reagent strips. Hepatology 2003;37:893-896. Erratum in Hepatology 2003;37 (6): 1503.
31. Vanbiervliet G, Rakotoarisoa C, Filippi J, et al. Diagnostic accuracy of a rapid urine-screening test (Multistix8SG) in cirrhotic patients with spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2002;14 (11): 1257-1260.
32. Butani RC, Shaffer RT, Szyjkowski RD, et al. Rapid diagnosis of infected ascitic fluid using leukocyte esterase dipstick testing. Am J Gastroenterol 2004:99:532-537.
33. Sapey T, Mena E, Fort E, et al. Rapid diagnosis of spontaneous bacterial peritonitis with leukocyte esterase reagent strips in a European and American center. J Gastroenterol Hepatol 2005;20: 187-192.
34. Runyan BA, Kaplan MM, Bonis PAL. Diagnosis of spontaneous bacterial peritonitis. UpToDate.com. Available at: www.uptodate. com. May 28, 2008.
35. Nguyen-Khac E, Cadranel JF. Thevenot T, Nousbaum J-B. Review 210 article: Utility of reagent strips in diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther 2008;28:282-288.
36. Akriviadis EA, Runyon BA. Utility of an algorithm in differentiation spontaneous from secondary bacterial peritonitis. Gastroenterology 1990;98:127-133.
37. Garrison RN, Cryer HM, Howard DA, et al. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984;199:648-655.
38. Bhuva M, Ganger D, Jensen D. Spontaneous bacterial peritonitis: An update on evaluation, management, and prevention. Am J Med 1994;97:169-175.
39. Scheckman P, Onderdonk AB, Bartlett JG. Anaerobes in spontaneous peritonitis (letter). Lancet 1977;2:1223.
40. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457-462.
41. Rimola A, Salmeron JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study. Hepatology 1995;21:674-679.
42. Mercader J, Gomez J, Ruiz J, et al. Use of ceftriaxone in the treatment of bacterial infections in cirrhotic patients. Chemotherapy 1989;35:23-26.
43. Gomez-Jimenez J, Ribera E, Gasser I, et al. Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients. Antimicrob Agents Chemother 1993;37:1587-1592.
44. Mesquita MA, Balbino EPS, Albuquerque RS, et al. Ceftriaxone in the treatment of spontaneous bacterial peritonitis: Ascitic fluid polymorphonuclear count response and short-term prognosis. Hepatogastroenterology 1997;44:1276-1280.
45. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document. J Hepatol 2000;32:142-153.
46. Ghassemi H, Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:77-93.
47. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis and multiorgan failure in cirrhosis. Semin Liver Dis 2008;28:26-42.
48. Franca AVC, Giordano HM, Seva-Pereira T, Soares EC. Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients. J Gastroenterol 2002;37:119-122.
49. Suzuki K, Takikawa Y. Marked improvement in the resolution of, and survival rates in, spontaneous bacterial peritonitis (editorial). J Gastroenterol 2002;37:149-150.
50. Angeloni S, Leboffe C, Parente A, et al. Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World J Gastroenterol 2008;14:2757-2762.
51. Dupeyron C, Mangeney N, Sedrati L, et al. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial prophylaxis. Antimicrob Agents Chemo 1994;38:340-344.
52. Campillo B, Dupeyron C, Ricardet J-P, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: Effects of long-term administration of norfloxacin. Clin Infect Dis 1998;26:1066-1070.
53. Fernandez J, Navasa M, Gomez J, et al. Bacterial infections in cirrhosis: Epidemiologic changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-148.
54. Singh N, Wagener MM, Gayowski T. Changing epidemiology and predictors or mortality in patients with spontaneous bacterial peritonitis at a liver transplant unit. Clin Microbiol Infect 2003;9:531-537.
55. Patterson DL, Mudder RR, Squier C, et al. Outbreak of infection vnth E. coli harboring extended-spectrum beta-lactamase (ESBL) in a liver transplant unit: Could norfloxacin administration to carriers contribute to control? Clin Infect Dis 2001;33:126-128.
56. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409.
57. Gines P, Guevara M, De Las Heras D, Arroyo V. Review article: Albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther 2002 (16 Suppl 5): 24-31.
58. Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-599.
59. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebc-controlled trial. Hepatology 1990;12:716-724.
60. Lontos S, Gow PJ, Vaughan RB, Angus PW. Norfloxacin and trimethoprim-sulfamethoxazole have similar efficacy in the prevention of spontaneous bacterial peritonitis. Hepatology 2008; 23:252-255.
61. Assy N, Schlessinger S, Miron D, Hussein O. Cycling of antibiotics for the prophylaxis of recurrent spontaneous bacterial peritonitis in a cirrhotic patient. World J Gastroenterol 2005;11: 6407-6408.
62. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27:1207-1212.
63. Vivas S, Rodríguez M, Palacio MA, et al. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001;46:2752-2757.
64. Bernard B, Cadranel JF, Valla D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: A prospective study. Gastroenterology 1995;108:1828-1834.
65. Pohl J, Pollmann K, Sauer P, et al. Antibiotic prophylaxis after variceal hemorrhage reduces incidence of early rebleeding. Hepatogastroenterology 2004;51:541-546.
66. Soares-Weiser K, Brezis M, Tur-Kaspa R, Leibovici L. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002;CD002907.
67. Rimola A, Bory F, Teres J, et al. Oral, non-absorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985;5:463-467.
68. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992;103:1267-1272.
69. Blaise M, Pateron D, Trinchet JC, et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1994;20:34-38.
70. Hsieh WJ, Lin HC, Hwang SJ, et al. The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 1998; 93:962-966.
71. Fernandez J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin vs. ceftriaxone in the prophylaxis of infection in patients with advanced cirrhosis and hemorrhage. Gastroenterol 2006;131: 1049-1056.
72. Llach J, Rimola A, Navasa M, et al. Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. Hepatology 1992;16:724-727.
73. Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
74. Terg R, Fassio E, Guevara M, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study. J Hepatol 2008;48:774-779.